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730Objective: Thymectomy is a well-defined therapeutic option for patients with myasthenia gravis; however, con-
troversies still exist about the surgical approach, indication, and timing for surgery. We reviewed our experience
reporting surgical and neurologic results after robotic thymectomy in patients with myasthenia gravis.
Methods: Between 2002 and 2010, 100 patients (74 female and 26 male; median age, 37 years) underwent
left-sided robotic thymectomy using the da Vinci robotic system (Intuitive Surgical, Inc, Sunnyvale, Calif).
The Myasthenia Gravis Foundation of America classification was adopted for pre- and postoperative evaluation.
PreoperativeMyasthenia Gravis Foundation of America class was I in 10% of patients, II in 35% of patients, III
in 39% of patients, and IV in 16% of patients.
Results:Median operative time was 120 (60-300) minutes. No death or intraoperative complications occurred.
Postoperative complications were observed in 6 patients (6%) (bleeding requiring blood transfusions in 3, chy-
lothorax in 1, fever in 1, and myasthenic crisis in 1). Median hospital stay was 3 days (range, 2-14 days). His-
tologic analysis revealed 76 patients (76%) with hyperplasia, 7 patients (7%) with atrophy, 8 patients (8%)
with small thymomas, and 9 patients (9%) with normal thymus; ectopic thymic tissue was found in 26 patients
(26%). Clinical follow-up showed a 5-year probability of complete stable remission and overall improvement of
28.5% and 87.5%. Remission was significantly associated with preoperative I to II Myasthenia Gravis Foun-
dation of America class (P ¼ .02). A significant improvement rate was found in Myasthenia Gravis Foundation
of America class I to II (P¼ .03) and AbAchRþ (P¼ .04). A high percentage of patients interrupted or reduced
their medications.
Conclusions: Robotic thymectomy is a safe and effective procedure. We observed a neurologic benefit in a great
number of patients. A better clinical outcome was obtained in patients with early Myasthenia Gravis Foundation
of America class. (J Thorac Cardiovasc Surg 2013;145:730-6)Myasthenia gravis (MG) is a rare autoimmune disease that
affects neuromuscular transmission. A causal role has been
advocated for the thymus gland in the complex pathogene-
sis of this disease, and thymectomy is now an essential part
of the integrated treatment of nonthymomatous MG. How-
ever, much controversy still exists regarding the selection of
patients, extent of thymic resection, and appropriate surgi-
cal approach.1
A variety of surgical approaches for thymectomy have
been described, ranging from open (basic transsternal2 or
the more aggressive extended transcervical and trans-
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The Journal of Thoracic and Cardiovascular Surg(transcervical4 or video-assisted thoracoscopic thymec-
tomy5) approaches. Each approach has benefits and draw-
backs. Only nonrandomized retrospective case series have
been available for comparing operative approaches, and
the heterogeneity of patient selection, different timing and
type of surgery, several clinical classifications used, and dif-
ferent methods applied for evaluating the results, along with
many other confounding factors, have made a comparative
analysis complicated, if not impossible.1 Thus, a consensus
on the best practice has not been reached.
Because of the lack of data from prospective thymectomy
trials for patients withMG, clinicians must consider the best
balance among the extent of resection, morbidity, patient
acceptance, and results. The intrinsic characteristics of
MG, the problems related to immunosuppression, and the
generally young age of patients make the intraoperative
and postoperative management of patients with MG chal-
lenging. In an attempt to find the best compromise between
a complete thymic resection and minimizing the effect of
surgery on the patient, video-assisted thoracoscopic thy-
mectomy has been proposed as a valid alternative to open
approaches for patients with nonthymomatous MG. The in-
troduction of robotic instrumentation in the last decade has
increased the potential technical skill and safety of standardery c March 2013
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Sthoracoscopy and will eventually improve clinical results.6
However, almost all reported series on robotic thymec-
tomy7-11 have involved relatively few patients and short
follow-up periods. Furthermore, comparisons are difficult
because of a lack of standardized nomenclature.
We report our experience with robotic thymectomy in
100 consecutive patients with MG and provide data on the
surgical results and long-term neurologic outcomes, follow-
ing the Myasthenia Gravis Foundation of America (MGFA)
recommendations for MG clinical research standards.12PATIENTS AND METHODS
A retrospective analysis of a prospectively maintained database was
conducted for 100 patients affected by MG who received a unilateral,
3-port, left-sided robotic thymectomy (MGFA thymectomy classification:
class T-2c) performed by the Thoracic Surgery Division in Padua, Italy, us-
ing the da Vinci robotic surgical system (Intuitive Surgical, Inc, Sunnyvale,
Calif) between 2002 and 2010. All patients signed a detailed consent form
describing possible complications of thymectomy via a robotic approach.
The institutional review board approved this study.
The diagnosis of MG was based on clinical criteria, electromyography,
edrophonium chloride test results (Tensilon; ICN Pharmaceuticals, Inc,
Costa Mesa, Calif), and circulating AbAchR levels. Patients with negative
AbAchR results also were evaluated for anti-MuSK antibodies and
excluded from surgery when positive. Other exclusion criteria were radio-
logic evidence of invasive thymoma, the presence of adhesions (eg, previ-
ous thoracic surgery or pleuritis), the inability to perform single lung
ventilation, or a body mass index greater than 35. Twenty-six male patients
(26%) and 74 female patients (74%) with a median age of 37 years (inter-
quartile range [IQR], 25-47 years) were included in the study. The median
duration of preoperative symptoms was 11 months (IQR, 5-24 months); 66
patients were AbAchR positive, and 34 patients were seronegative. Data on
patient demographics, type and severity of MG, and intraoperative and
postoperative events (eg, complications, need for open conversion or addi-
tional ports or accesses, operative time, and length of hospital stay) were
collected.
Preoperative and postoperative clinical assessments were conducted by
a team of neurologists. Preoperative evaluation included a neurologic as-
sessment, chest radiography, computed tomography (or magnetic reso-
nance imaging in selected patients), electrocardiography, and spirometry.
Preoperative preparation included a reduction or an interruption of steroid
treatment whenever possible. Plasma exchange therapy or intravenous im-
munoglobulin treatments were administered to patients at risk for postop-
erative respiratory failure (history of respiratory muscle involvement or
recent worsening of symptoms) on the basis of the clinical judgment of
a neurologist and previous effective use.
The MGFA recommendations for clinical research standards classifica-
tion12 were followed for the clinical classification, preoperative and post-
operative therapy status, post-intervention clinical status evaluation, and
morbidity/mortality descriptions. Preoperative MGFA clinical classifica-
tions were as follows: class I in 10 patients, class IIa in 26 patients, class
IIb in 9 patients, class IIIa in 24 patients, class IIIb in 15 patients, classThe Journal of Thoracic and CaIVa in 8 patients, and class IVb in 8 patients. Preoperatively, 41 patients
were receiving single-drug therapy (2-drug therapy in 39 and 3 medica-
tions in 20). According to the MGFA recommendations, postintervention
status was described as follows: complete stable remission (CSR) (patients
without symptoms or signs of MG for at least 1 year and no therapy); phar-
macologic remission (same criteria as CSR except that the patient con-
tinues to take some form of medication, excluding cholinesterase
inhibitors); minimal manifestations (no symptoms or functional limitations
but some weakness detectable by careful examination), changes in status
(improved, unchanged, worse, exacerbation, and died of MG). CSR and
pharmacologic remission were calculated at the end of a minimal
12-month follow-up period.
Surgical Technique
In all patients, an extended thymectomy with en bloc resection of the
anterior mediastinal fat tissue was performed following Masaoka and col-
leagues’ criteria.2 The adipose tissue around the upper poles of the thymus,
both innominate veins, the retrosternal area, and the pericardium were re-
sected meticulously. The resection borders were the diaphragm caudally,
the thyroid gland cranially, and the phrenic nerves laterally. The surgical
technique has been described.8 In our series, our preference was for
a left-sided approach for technical, clinical, and anatomic reasons. As dem-
onstrated by R€uckert and colleagues,13 the larger part of the thymus is on
the left side. Furthermore, in approximately 72% of cases1 the thymus
gland is located lateral and under the left phrenic nerve, which is better
identified and safely dissected under direct vision from the left, whereas
the right phrenic nerve is partially protected by the superior vena cava in
the high mediastinum and may be easily identified and followed in the
lower part. All mediastinal fat tissue was removed that comprised the aor-
topulmonary window, which is a frequent side of ectopic thymic tissue, and
it is easier to reach by the left approach. To identify the location of the ec-
topic thymic tissue, the perithymic fat was sent for histopathologic exam-
ination, divided and classified on the basis of location: pretracheal
infrathyroid fat, fatty tissue in the aortopulmonary window, mediastinal
fat lateral to right and left phrenic nerves, and pericardial fat up to the di-
aphragm. Microscopically, the histologic types of the thymus were de-
scribed as hyperplastic, involuted, and thymoma. The foci of ectopic
thymic tissue with Hassall bodies in the excised cervicomediastinal fat
were searched for with hematoxylin–eosin staining.
Statistical Analysis
Qualitative variables were summarized as frequency distributions.
Quantitative data are described as median and first and third quartile
(IQR). The normality of the data distribution was assessed by the Sha-
piro–Wilk test. The probabilities of CSR and improvement were calculated
by cumulative analysis according to the Kaplan–Meier method. A univar-
iate analysis to potentially predict CSR and improvement was conducted
with the log-rank test. To fully understand the factors involved in the out-
comes, all the variables were entered in multivariate analysis by applying
the Cox regression model. Proportional hazards assumption was graphi-
cally checked. Differences in distributions were tested by means of the
chi-square test or Fisher exact test, as opportune.
To evaluate the significance of change of drug dosage over follow-up,
data on drug dosage were treated in the repeated-measures analysis with
drug dosage as the dependent data and time as repeated measures effect
(within-subject effect). Given that drug dosage was not normally distrib-
uted, nonparametric analysis of variance for repeated measurements was
applied. All the statistical procedures were performed with SAS version
9.1.2 (SAS Institute, Inc, Cary, NC).
RESULTS
All procedures were carried out endoscopically, with no
conversion to median sternotomy or thoracotomy. A fourthrdiovascular Surgery c Volume 145, Number 3 731
FIGURE1. Cumulative probability of CSR and improvement.CSR,Com-
plete stable remission.
TABLE 1. Statistical analysis of factors predicting complete stable
remission and improvement
Factor
5-y CSR
rate (%) P* Py
5-y
improvement
rate (%) P* Py
Preoperative MGFA .002 .02 .04 .03
Class I-II (n ¼ 45) 46.8 94.2
Class III-IV (n ¼ 55) 18.2 84.8
Gender .86 .77 .68 .39
Male (n ¼ 26) 30.5 86.4
Female (n ¼ 74) 28.1 88.9
AchR antibodies .19 .17 .04 .04
Positive (n ¼ 66) 23.4 91.3
Negative (n ¼ 34) 40.7 83.1
Histology .32 .41 .30 .15
Benign thymus (n ¼ 92) 31.3 86
Thymoma (n ¼ 8) 12.5 100
Age .20 .79 .31 .39
36.5 y (n ¼ 50) 39.4 91.6
>36.5 y (n ¼ 50) 21.7 86
Ectopic thymic tissue .08 .19 .49 .63
Present (n ¼ 26) 21.4 95.2
Absent (n ¼ 74) 33.2 86.7
Preoperative duration of
symptoms
.33 .28 .84 .91
12 mo (n ¼ 58) 32.8 91.4
>12 mo (n ¼ 42) 22.2 84.1
Significant P values are in bold. CSR, Complete stable remission;MGFA,Myasthenia
Gravis Foundation of America. *Unadjusted P values performed by log-rank test.
yAdjusted P values performed by Cox multivariate regression.
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Saccess was used in 3 patients: In 2 patients, a fourth access
on the right side was used to introduce optics for better vi-
sualization of the right phrenic nerve, and in 1 patient, a cer-
vicotomy was required to complete dissection of the thymic
upper horns. No death or intraoperative complications oc-
curred, and all patients were extubated in the operating
room within 1 hour after surgery. The median operative
time was 120 minutes (IQR, 106-159 minutes), median
time to chest tube removal was 1 day (IQR, 1-2 days),
and median hospitalization time was 3 days (IQR, 2-4
days). Postoperative complications occurred in 6 patients
(6%). In our early experience, 1 patient had a chylothorax
on postoperative day 2; this prolonged hospitalization
(2 weeks) and was successfully managed with conservative
treatment. A hemothorax developed in 3 patients, but it did
not require reoperation and was successfully managed with
a chest tube and blood transfusions. Fever that required pro-
longed treatment with antibiotic therapy developed in 1 pa-
tient. A postoperative myasthenic crisis necessitated
intubation and mechanical ventilation for 24 hours in 1 pa-
tient. Pathologic examinations revealed 76 thymic hyper-
plasias, 7 atrophies, 9 normal thymuses, and 8 small (1-3
cm) thymomas. The median weight of the specimens (thy-
mus and perithymic tissue) was 44 g (IQR, 31-56 g). The
pathologic analysis of perithymic and mediastinal fat tissue
identified the presence of ectopic thymic tissue in 26 pa-
tients (26%). All patients were neurologically evaluated
at 12 or more months after surgery (median, 67 months;
IQR, 37-91 months). At the last follow-up (May 2012), 98
patients were alive, and 2 patients had died 25 and 29
months postoperatively of extrathymic cancers (gastric can-
cer and leukemia). No evidence of tumor recurrence was
found in patients with thymoma. The 5-year CSR rate was
28.5%, and the 5-year improvement (all patients with the
following MGFA postintervention status: pharmacologic
remission and minimal manifestation) rate was 87.5%
(Figure 1). Median time to improvement was 17.9 months
(IQR, 15-20.2 months). Univariate analysis of prognostic
factors (Table 1) for CSR identified a significantly better re-
sult in patients with preoperative MGFA classes I and II
compared with MGFA classes III and IV (P ¼ .002;
Figure 2, A). A trend for a better CSR rate was seen in pa-
tients with an absence of ectopic thymic tissue (P ¼ .08;
Figure 2, B). A significant improvement rate was observed
in patients with MGFA classes I and II (P ¼ .04; Figure 2,
C) and positive AbAchR results (P ¼ .04; Figure 2, D). No
significant differences were observed in age, sex, histology,
or symptom onset before surgery. The results from multi-
variate analysis confirmed the statistical significance of as-
sociation between MGFA classes I and II and complete
remission (multivariate adjusted P ¼ .02) and between
MGFA classes I and II and positive AbAchR and 5-year im-
provement (multivariate adjusted P ¼ .03 and .04, respec-
tively). The post-intervention therapy status assessment732 The Journal of Thoracic and Cardiovascular Surg(Table 2) showed a suspension or reduction in the median
dose of cholinesterase inhibitor in 69.1% of patients and
a suspension or reduction of prednisone in 89.4%. Signifi-
cant reductions in the median cholinesterase inhibitor dose
(P ¼ .002) and median prednisone dose (P ¼ .0003) were
observed over a 10-year follow-up compared with the pre-
operative dosage (Figure 3, A and B).ery c March 2013
FIGURE 2. Cumulative probability of CSR on the basis of MGFA class (A) and presence or absence of ectopic thymus (B). Cumulative probability
of improvement on the basis of MGFA class (C) and AbAchR status (D). CSR, Complete stable remission; MGFA, Myasthenia Gravis Foundation of
America.
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SDISCUSSION
Despite general agreement on the beneficial role of thy-
mectomy for patients with MG, no prospective randomized
trial has examined whether thymectomy is superior to med-
ical treatment, although an ongoing international multicen-
ter randomized clinical trial is comparing thymectomy and
therapy with prednisone alone.14 In addition to the low level
of evidence supporting thymectomy, controversy also exists
regarding the best surgical approach, the optimal extent of
resection and degree of invasiveness, and the selection cri-
teria for surgical candidates. Numerous thymectomyTABLE 2. Myasthenia Gravis Foundation of America pre- and
postintervention therapy status
Drugs Preoperative
Postoperative
Interrupted Reduced
Cholinesterase inhibitors 94 (94%) 36 (38.3%) 29 (30.8%)
Prednisone 56 (56%) 23 (41.1%) 27 (48.2%)
Azathioprine 26 (26%) 9 (34.6%) 5 (19.2%)
Cyclosporine 4 (4%) 4 (100%)
Plasma exchange therapy,
chronic
11 (11%) 9 (81.8%) 2 (18.2%)
IVIg therapy, chronic 12 (12%) 11 (91.7%)
IVIg, Intravenous immunoglobulin.
The Journal of Thoracic and Catechniques with different degrees of invasiveness have
been described, all with similar results.2-11 Jaretzki1 noted
that these reports suffer from a lack of uniform reporting
with respect to disease severity, extent of thymectomy, re-
sponse to thymectomy, specimen histology, and follow-up
length, as well as the application of nonstandard statistical
methods. In 2000, the MGFA published recommendations
for MG clinical research standards. A series of preoperative
and postoperative classifications were proposed in an at-
tempt to give a common and uniform language for further
studies.12 Unfortunately, only a few studies have adopted
these recommendations; thus, controversy, particularly re-
garding the best surgical approach, remains. Ideally, the
less-invasive surgical technique is desirable, assuming the
results are equivalent. Compared with conventional trans-
sternal techniques, minimally invasive techniques have be-
come increasingly popular because of their low procedural
morbidity and mortality, short hospital stay, optimal cosm-
esis, minor surgical access trauma and postoperative pain,
better preservation of pulmonary function, and similar effi-
cacy.4,5,7,8,15 Thoracoscopic thymectomy combines the
advantages of minimally invasive techniques with a good
view of the anterior mediastinum, so that an extended
thymectomy can be performed as needed. Disadvantagesrdiovascular Surgery c Volume 145, Number 3 733
FIGURE 3. Postoperative reduction over time of the median dose of cho-
linesterase inhibitor (A) and prednisone (B) compared with the basal pre-
operative treatment Symbols are median, line at the lower end is the first
quartile, line at the upper end is the third quartile.
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Sof the conventional thoracoscopic technique include
a 2-dimensional view of the operative field and the fact
that the arms do not articulate, making it difficult to operate
in the contralateral mediastinum and in the neck around cor-
ners in a fixed 3-dimensional space. In the last decade, ro-
botic systems have been successfully introduced to
thoracic surgery for treating various diseases, especially
diseases of the anterior mediastinum.16 The da Vinci surgi-
cal system consists of a master console and a surgical ma-
nipulator (slave unit) with 2 instrument arms and 1
camera arm. The camera consists of a device with
3-dimensional vision that affords the best possible view of
the operative site. The da Vinci surgical endo-wrists, with
articulated movements that permit a full 7 degrees of free-
dom and 360 degrees of rotation, improve maneuverability,
making it safe and comfortable to dissect vascular (innom-
inate vein) and nervous (phrenic nerve) structures. All of
these characteristics have potentially increased not
only the dexterity and safety but also the radicality of con-
ventional video-assisted thoracoscopic thymectomy by
enhancing the dissection, particularly for remote and
difficult-to-reach areas, of the contralateral mediastinum
and neck. A recent study by R€uckert and colleagues6 retro-
spectively compared the results of nonrobotic thoraco-
scopic and robotic thymectomy in patients with MG. A
significantly increased rate of CSR (39.2% vs 20.3%;
P ¼ .01) was observed in the robotic group; this result pre-
sumably could be related to the better extension and radical-
ity of resection. Most experiences in robotic thymectomy734 The Journal of Thoracic and Cardiovascular Surghave reported low conversion (<5%) and morbidity
(<10%) rates and short hospital stays (<4 days).7-11 Our
findings agree with these results, because we had no open
conversion, 6% complications, no nervous or major
vascular injuries, and a median hospital stay of 3 days.
Our clinical long-term results are in line with recent studies
adopting the MGFA recommendations and reporting CSR
rates ranging from 28%17 to 42.8%5 for conventional thor-
acoscopic thymectomy and from 27%11 to 42%7 for ro-
botic thymectomy. Likewise, a wide range of CSR rates
have been reported for open transsternal and transcervical
approaches (17%-34%).4,18 This variability may depend
on several factors, including different follow-up durations
(18-45 months), heterogeneity of patient characteristics
(thymomatous and nonthymomatous, ocular and general
MGwith different classes of severity, variable length of pre-
operative symptoms), clinical evaluations not performed by
a neurologist, and different practices among neurologists
with regard to prescriptions and management strategy for
weaning off drugs after thymectomy. Our series suffered
from the same limitation bias, because we had a heteroge-
neous population of patients with both ocular (11%) and
generalized MG, nonthymomatous and thymomatous
(8%) MG, and ages less than and more than 40 years
(39%). It is now fairly well accepted that thymectomy
should be offered to young patients with generalized MG.
However, uncertainties remain concerning the role of thy-
mectomy for patients with purely ocular symptoms, sero-
negative disease, late-onset disease, and involvement of
ectopic thymic tissue. Between 30% and 70% of patients
with initial ocular symptoms will eventually develop gener-
alized myasthenia. Thus, some authors19 have advocated
surgery for patients with purely ocular MG. Our practice
is to not exclude these patients, particularly when the symp-
toms are disabling and poorly controlled by medical ther-
apy. Our results show significantly higher rates of CSR
and improvement for those patients with ocular and mildly
severe MG. A similar finding was reported by Jaretzki.1 In
contrast, a review conducted by the American Academy of
Neurology reported better clinical improvement after thy-
mectomy in cases with more severe MG.19 The indication
for thymectomy in AbAchR-negative patients is controver-
sial. This group is heterogeneous; some patients show false-
negative results, whereas others have MuSK antibodies. A
retrospective cohort study showed similar postoperative
courses in AbAchR-negative and AbAchR-positive pa-
tients.20 In another study, the presence of MuSK antibodies
predicted a poor outcome.21 Available evidence suggests
that thymectomy should not be recommended in MuSK
antibody-positive patients. We followed this recommenda-
tion; all seronegative patients were tested for the presence
of MuSK antibodies, and only double seronegative patients
were eligible for surgery. Our cohort of seronegative pa-
tients had a higher, but not significantly higher, CSR rateery c March 2013
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a significantly poorer improvement rate was observed in se-
ronegative patients. Some studies have found significantly
better clinical results in young patients with short disease
duration.5,21 The robotic procedure has an advantage of
being more easily and readily accepted by both
neurologists and young patients, because it produces good
cosmetic results and is less invasive. In our series, the
median duration of preoperative symptoms was 11
months, reflecting an early referral policy and rapid
acceptance. Despite no significant difference in CSR
based on age and symptom onset, a trend toward CSR
was observed in young patients with short (<1 year)
disease duration before surgery. Rates of detecting ectopic
thymic tissue are 22% to 39.5% in reported studies and
reached 26% in our experience. Some authors22 have high-
lighted the importance of ectopic thymic tissue in the main-
tenance of disease and have indicated that it is a negative
prognostic factor for remission. Our series of patients
with pathologic evidence of ectopic thymus tended to
have a lower probability for CSR.
CONCLUSIONS
Our study reports the outcome of a large group of patients
who underwent robotic thymectomy followed by a long
follow-up period. We demonstrated that robotic thymec-
tomy is a technically sound operation, with low morbidity
and short hospitalization. Neurologic long-term results
were good for both CSR and clinical improvement, with
a significant reduction in medication over time. In addition,
the optimal cosmetic results and minimal invasiveness of
this type of surgery were associated with its high acceptance
by both patients and neurologists, resulting in early referral
and potential further improvement in outcome. A close col-
laboration between thoracic surgeons and neurologists is
important in planning the best treatment strategy to achieve
optimal results.
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Dr Mithran Sukumar (Portland, Ore). You were succinct in
presenting your surgical results and neurologic outcomes after
thymectomy for myasthenia, particularly in the effect that it has
on the postoperative management of these patients. I have 2 ques-
tions for you.
The first is in regard to bleeding with robotic thymectomy.Would
you briefly discuss the possible sites and causes? Is there an inci-
dence of catastrophic bleeding, and how would you manage that?
Dr Marulli. All patients with postoperative bleeding did not
have a re-do operation, so we can suppose looking at the chest
x-ray that the bleeding was from one of the ports, probably in 2
cases from the port of the camera and in 2 cases from the port of
the parasternal area because these ports receive stress during ma-
neuvers and the parasternal port is the port that we use to remove
the specimen; thus, it may be damaged. There is no relationship
with the experience. Recently, we had another case of bleeding
in which we performed reoperation. The bleeding was from the
thoracic vessels, probably because the resident damaged therdiovascular Surgery c Volume 145, Number 3 735
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Svessels during the small opening of the access. There was no intra-
operative bleeding, but eventually its management could be diffi-
cult, probably requiring an open conversion.
Dr Sukumar. My second question is to deal with this whole
idea of robotic thymectomy. Your slide presented the possible ad-
vantages of robotic thymectomy, but would you discuss the real
disadvantages at this time?
DrMarulli. There are some disadvantages. Some are important
and some are less important. For example, one of the most com-
mon disadvantages is the absence of tactile feedback. This is not
an important disadvantage because superior vision is enough to
overcome this limitation. The main technical disadvantage is prob-
ably when you have bleeding from a large vessel. The necessity for
emergency conversion can be more difficult for 2 reasons. The first
reason is that the main surgeon is far from the patient and is not
scrubbed, so you should have an assistant who should be able to
do an emergency conversion. Moreover, the emergency conversion
can be difficult because the robot is over the patient, so you do not
have much space. On the other hand, the control of the vessel may
be better because of the high degree and complexity of the move-
ments allowed by robotic instruments, so you can grasp the vessel
to temporarily control the bleeding. Another limitation is the cost.
The fixed cost can be reduced by using the robot in amultidisciplin-
ary setting. In our hospital we use the robot with the urologist, gy-
necologist, and general surgeons. Although the cost of the
disposable materials is obviously high, it is not recoverable. An-
other limitation is the absence of suction devices, which can be
a limitation not only for the thymectomy, which is an easy tech-
nique with no need for suction, but also for the lobectomy.
Dr Joseph Shrager (Stanford, Calif). All the robotic talking
points that we commonly hear about are nice (eg, reduction of
tremor), and it is probably fun to do a thymectomy that way. But
we have published that transcervical thymectomy has almost no
cost, there is no fancy equipment, and we have a higher CSR
rate than you have published. You can also do it as an outpatient
procedure. There is essentially no pain for the patient and almost
no morbidity. The only bad thing about that procedure is that it
is hard to find places where people can learn how to do it. It is
hard to justify all the costs of robot—given the talks we have heard
during this whole meeting about economics—when you can do
this thymectomy quickly and with at least as good results with
nothing other than a little substernal retractor.
Dr Marulli. I agree with you. I know your work, and I think
transcervical thymectomy can become the standard of care in
this kind of patient. We need more reliable results because at the
time only a few articles address these types of results. Moreover,
I have 2 concerns. Although I never used the transcervical ap-
proach, my chief had a good experience with this approach, and
he considers the transcervical technique somewhat difficult to
learn in comparison with the robot technique, so my concern is
the learning curve. Moreover, your experience is the best experi-
ence. You have 8% open conversion if I remember, probably split
conversion, which is higher than the robotic technique. We have
0% conversion, so I do not know if the technique is ready to be736 The Journal of Thoracic and Cardiovascular Surgwidely used, but it absolutely is the best of mini-invasive tech-
niques in my opinion.
Dr Shrager. Almost all the conversions were in cases that I
would not now recommend the procedure be attempted, where
we were trying to do it for a small thymoma, and I would not rec-
ommend it for those cases. Also, you learn after a while that it can-
not be done if the patient cannot really extend his or her neck well.
It is not hard to learn; it is just that there are only a few places or
people who can teach you how to do it. I mean, the residents can do
it after basically seeing one of them. It is simple, and I would invite
anybody who wants to learn how to do it. Cases are not all that fre-
quent, but anyone who wants to learn could come to Stanford and
see how it is done.
Dr Marulli. I like the transcervical thymectomy. My experi-
ence in the robotic thymectomy was positive, and the learning
curve with robotic technique was easy.
Dr David Follette (Sacramento, Calif). I agree with Joe about
the transcervical thymectomy. Over the years at this meeting, we
have heard a number of talks. I have never seen a nicer one describ-
ing the robotic technique, but my comment and question is not can
you do it but should you do it? The whole field of robotic surgery
with few exceptions has never been proven to improve long-term
outcomes or mortality. It improves cosmetics; you do not get a ke-
loid. As we learned this morning, procedures that are fancy and
look great on the Internet may not really be justified unless there
are outcomes. Thoracic surgery has spent a lot of our time, espe-
cially in the world of oncology, trying to figure out what is best
for the patient before adopting new techniques. My concern is,
and my philosophy has evolved, if you have 2 techniques and
your patient is worried about cosmetics and wants to pay the extra
$35,000 out of pocket, so be it unless you really have evidence that
the long-term outcome, not just 1 day shorter in the hospital or
nicer scar, is better. Have you compared, because you have an ex-
tensive experience and a wonderful team, the actual long-term out-
come of standard techniques versus robotic techniques in terms of
certain patients who have recidivism of their myasthenia symp-
toms long-term and increased doses of medication. Have you
made an effort to look at the long-term outcomes, and can you hon-
estly say there is a distinct benefit to the patient that justifies the
significant increase in cost other than cosmesis? People in the
United States, if they want cosmetic surgery, they pay for it out
of their pockets.
Dr Marulli. I do not have a reply for this question because we
did not compare with the previous technique, and a retrospective
comparison is not useful, so we have to wait for major data from
studies adopting the MGFA classification, the same criteria. We
shifted from the classic conventional video-assisted thoraco-
scopic approach to the robotic approach. From a technical point
of view, there is a big difference. In our previous experience, we
had at least 30% of patients who required a further transcervical
approach and approximately 10% of patients required an open
conversion, so from a technical point of view, the resection is
safer, bigger, and more radical. For long-term results, I have
no reply for you.ery c March 2013
